ACC latest: Lilly, Merck, Pfizer, Novartis and more unveil key data

Tracy Staton You missed the American College of Cardiology meeting. That's OK. The most newsworthy research coming out of the meeting is gathered right here, with almost every Big ...

Lilly, BI approach CV-benefit label change for SGLT2 med Jardiance

Carly Helfand Eli Lilly and Boehringer Ingelheim are one step closer to an important label change for SGLT2 contender Jardiance. FiercePharma News

BMS, Lilly, Sanofi and Novartis top Big Pharma’s growth fortunes for next decade: Analysts

Tracy Staton Predicting the future–particularly when it comes to Big Pharma's prospects for growth and earnings–is a favorite pastime among industry-watchers. Even better ...

Lilly and Incyte shoot for FDA approval with an oral RA drug

Damian Garde Partners Eli Lilly and Incyte filed an oral rheumatoid arthritis treatment for FDA approval, hoping to launch an agent that can steal market share from blockbuster injectables. FierceBiotech ...

FDA approves Lilly and Boehringer’s take on Sanofi’s top-selling insulin

Damian Garde Partners Eli Lilly and Boehringer Ingelheim inched closer to challenging Sanofi's best-selling insulin, winning FDA approval for their take on the blockbuster Lantus ...

Lilly and Merck pair ‘breakthrough’ therapies in latest cancer collaboration

Damian Garde Eli Lilly and Merck are expanding their oncology partnership to study a combination of the former's top cancer prospect with the latter's blockbuster immunotherapy. FierceBiotech ...

Lilly backs a $25M round for anti-inflammatory startup Symic

Damian Garde San Francisco's Symic raised $ 25 million to fund its work on a pair of anti-inflammatory medicines targeting the extracellular matrix, recruiting Eli Lilly to lead ...

Lilly, Sanofi, Novo among many pharma players to throw off big price gains in H1

Eric Palmer The first half of the year has provided a good ride for Big Pharma and its investors with indices up in the U.S. and Europe. Even Japanese drugmakers avoided the side effects ...

J&J sets up shop at Karolinska Institutet; Lilly, Zealand scrap R&D pact; Mapi raises $10M

Nick Paul Taylor In this week's EuroBiotech Report, Johnson & Johnson added another outpost to its burgeoning network of startup-scouting units. The J&J-Karolinska Institutet ...

BMS, focused on immuno-oncology, turns Erbitux over to Eli Lilly

Eric Palmer Erbitux is one of the top 10 best selling cancer drugs in the world and for years Bristol-Myers Squibb has sold it in the U.S. But Erbitux no longer fits in the sweet spot ...

Takeda taps Lilly exec to run U.S. unit, adding a woman to its all-male exec team

Tracy Staton Takeda has chosen a woman to run its U.S. pharma business, just weeks after new CEO Christophe Weber said he was unhappy with the gender balance in the Japanese drugmaker's ...

Lilly and Boehringer roll toward EU approval with diabetes combo

Damian Garde Eli Lilly and Boehringer Ingelheim secured a recommendation from European regulators for their combination diabetes treatment, making for a likely continental approval ...
Page 1 of 612345...Last »
© 2017 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS